HSCS
Heart Test Laboratories Inc. Common Stock
NASDAQ: HSCS · HEALTHCARE · MEDICAL DEVICES
$1.98
-1.00% today
Updated 2026-04-29
Market cap
$6.40M
P/E ratio
—
P/S ratio
738.41x
EPS (TTM)
$-4.49
Dividend yield
—
52W range
$2 – $6
Volume
0.0M
Heart Test Laboratories Inc. Common Stock (HSCS) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $64182.00 | $25604.00 | $14373.00 | $5150.00 | $18600.00 | $4350.00 |
| Revenue growth (YoY) | — | -60.1% | -43.9% | -64.2% | +261.2% | -76.6% |
| Cost of revenue | $110287.00 | $44276.00 | $34456.00 | $29711.00 | $101214.00 | $129836.00 |
| Gross profit | $-46105.00 | $-18672.00 | $-20083.00 | $-24561.00 | $-82614.00 | $-125485.00 |
| Gross margin | -71.8% | -72.9% | -139.7% | -476.9% | -444.2% | -2884.7% |
| R&D | $2.04M | $1.71M | $3.00M | $2.46M | $2.88M | $4.39M |
| SG&A | $1.80M | $874620.00 | $1.71M | $3.65M | $3.44M | $3.97M |
| Operating income | $-3.82M | $-2.57M | $-4.71M | $-6.11M | $-6.31M | $-8.35M |
| Operating margin | -5949.0% | -10030.2% | -32765.6% | -118698.3% | -33902.0% | -192013.1% |
| EBITDA | $-3.74M | $-2.29M | $-4.43M | $-6.08M | $-6.16M | $-8.14M |
| EBITDA margin | -5834.2% | -8928.7% | -30822.2% | -118139.8% | -33096.7% | -187053.3% |
| EBIT | $-3.81M | $-2.32M | $-4.46M | $-6.11M | $-6.25M | $-8.26M |
| Interest expense | $2811.00 | $132454.00 | $371619.00 | $243174.00 | $354080.00 | $500453.00 |
| Income tax | $22704.00 | $129003.00 | $-250200.00 | $484.50M | $-95133.00 | — |
| Effective tax rate | -0.6% | -5.6% | 4.9% | 101.3% | 1.4% | 0.0% |
| Net income | $-3.81M | $-2.45M | $-4.83M | $-6.35M | $-6.61M | $-8.77M |
| Net income growth (YoY) | — | +35.7% | -96.9% | -31.6% | -3.9% | -32.7% |
| Profit margin | -5938.0% | -9577.3% | -33592.6% | -123384.3% | -35511.9% | -201499.5% |